Elan Corp

Elan Corp. may move its headquarters to the U.S. because most of the management of Ireland's biggest drug maker will be located in the world's largest pharmaceutical market. The company appointed former Merrill Lynch & Co. executive G. Kelly Martin as president and chief executive. Martin said he plans to be based on the West Coast; Chairman Garo Armen is based in New York.

Elan Corp., Ireland's biggest drug maker, said it would pay $75 million to settle a shareholder lawsuit and a $15-million fine to resolve a Securities and Exchange Commission complaint related to the company's accounting. The company said $35 million of the settlement's cost would be covered by insurance. The company did not admit wrongdoing.

Elan Corp.'s top two executives lost their jobs at the Irish drug maker, whose shares have tumbled more than 90% since an accounting probe by the Securities and Exchange Commission began in February. Former Chairman and Chief Executive Donal Geaney, 51, and Vice Chairman Thomas Lynch, 45, agreed to step down. The board determined a change was necessary, new Chairman Garo Armen said. Elan was worth about $23 billion in June 2001, before the U.S.

Elan Corp. may move its headquarters to the U.S. because most of the management of Ireland's biggest drug maker will be located in the world's largest pharmaceutical market. The company appointed former Merrill Lynch & Co. executive G. Kelly Martin as president and chief executive. Martin said he plans to be based on the West Coast; Chairman Garo Armen is based in New York.

Elan Corp., Ireland's biggest drug maker, said it would pay $75 million to settle a shareholder lawsuit and a $15-million fine to resolve a Securities and Exchange Commission complaint related to the company's accounting. The company said $35 million of the settlement's cost would be covered by insurance. The company did not admit wrongdoing.

Elan Corp., a Dublin-based drug maker whose shares have declined 88% in the last year, plans to exit from businesses and cut its locations by half in response to investor pressure, the Sunday Times reported, citing Chairman and Chief Executive Donal Geaney. Elan today will say it plans to focus on two of its five product areas, neurology and pain killers, and quit acute care, cancer treatment and dermatology, the newspaper said.

Fast-growing pharmaceutical company Elan Corp. said Monday that it was boosting its U.S. presence through a $1.8-billion stock deal to buy San Diego-based Dura Pharmaceuticals Inc. Dura markets and sells prescription products that treat infectious diseases and respiratory conditions. Elan, whose headquarters are in Dublin, Ireland, and whose U.S. operations are based in San Diego, said the deal would add $300 million in revenue in 2001 and double the size of its U.S.

Elan Corp., a struggling Irish drug company, has ended its collaboration with Isis Pharmaceuticals of Carlsbad to develop a drug to treat hepatitis C.

On Assignment Inc., Calabasas, has been added to the Standard & Poor's Small Cap 600 Index, replacing Liposome Co., which has been acquired by Elan Corp. based in Ireland. On Assignment Inc. provides temporary staffing services to the scientific, health care and environmental industries.

Elan Corp.'s top two executives lost their jobs at the Irish drug maker, whose shares have tumbled more than 90% since an accounting probe by the Securities and Exchange Commission began in February. Former Chairman and Chief Executive Donal Geaney, 51, and Vice Chairman Thomas Lynch, 45, agreed to step down. The board determined a change was necessary, new Chairman Garo Armen said. Elan was worth about $23 billion in June 2001, before the U.S.

Elan Corp., a Dublin-based drug maker whose shares have declined 88% in the last year, plans to exit from businesses and cut its locations by half in response to investor pressure, the Sunday Times reported, citing Chairman and Chief Executive Donal Geaney. Elan today will say it plans to focus on two of its five product areas, neurology and pain killers, and quit acute care, cancer treatment and dermatology, the newspaper said.

Fast-growing pharmaceutical company Elan Corp. said Monday that it was boosting its U.S. presence through a $1.8-billion stock deal to buy San Diego-based Dura Pharmaceuticals Inc. Dura markets and sells prescription products that treat infectious diseases and respiratory conditions. Elan, whose headquarters are in Dublin, Ireland, and whose U.S. operations are based in San Diego, said the deal would add $300 million in revenue in 2001 and double the size of its U.S.

Irish drug maker Elan Corp. said that it agreed to acquire Neurex Corp., a Menlo Park-based drug maker specializing in pain medication, in a stock swap worth $700 million. Elan, based in Dublin, has spent $2 billion making acquisitions in the last two years. The company is branching into a new area with the acquisition of Neurex and its drugs to treat pain.